Add-on Acquisition • Medical Products

Thoratec Acquires Apica Cardiovascular

On July 2, 2014, Thoratec acquired medical products company Apica Cardiovascular for 75M USD

Acquisition Context
  • This is Thoratec’s 5th transaction in the Medical Products sector.
  • This is Thoratec’s 3rd largest (disclosed) transaction.
  • This is Thoratec’s 1st transaction in Ireland.

Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free


M&A Deal Summary

Date July 2, 2014
Target Apica Cardiovascular
Sector Medical Products
Buyer(s) Thoratec
Deal Type Add-on Acquisition
Deal Value 75M USD

Target Company

Apica Cardiovascular

Galway, Ireland
Apica Cardiovascular is a medical device company dedicated to establishing a new standard of care for transapical access and closure. The Company has developed a novel platform technology, which enables transapical delivery of aortic valves, mitral valves and other devices used in the treatment of Structural Heart Disease.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Thoratec

Pleasanton, California, United States

Category Company
Founded 1976
Sector Medical Products
Employees950
Revenue 503M USD (2013)
DESCRIPTION

Thoratec Corporation is a medical device company with a product portfolio for treating advanced heart failure patients. Thoratec develops, manufactures and markets proprietary medical devices used for circulatory support. Thoratec Corporation was established in 1976 and is headquartered in Pleasanton, California.


Deal Context for Buyer #
Overall 5 of 5
Sector: Medical Products 5 of 5
Type: Add-on Acquisition 2 of 2
Country: Ireland 1 of 1
Year: 2014 1 of 1
Size (of disclosed) 3 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-01 Terumo-DuraHeart II Ventricular Assist System

Japan

DuraHeart II ventricular assist system, is an ultra-compact, full-support, centrifugal flow chronic VAD utilizing a unique technology foundation known as "force balance" suspension. The device utilizes primary magnetic forces, balanced by hydrodynamic support, to achieve consistent gaps across the operating range of the pump, independent of pump speed.

Buy $57M